Identifying breakthroughs and filling gaps in the treatment landscape
Directing research to the areas of greatest need.
Funding trials that benefit children over research for research sake.
Developing streamlined clinical trials that quickly advance promising options.
SKC Presence in the Research Landscape
For more than a decade, Solving Kids’ Cancer has earned a seat at the table among some of the most inspiring researchers and like-minded organizations that are making a significant impact in the pediatric cancer research landscape.
Collaborating with pediatric cancer stakeholders across the globe, SKC advocates in New York and London serve on many advisories and working groups to solve kids' cancer.
SKC participates in consortiums, coalitions, and committees worldwide.
Member, Pediatric Drug Development, "Fit for Filing," ACCELERATE Working Group, (2019-present)
Member, Pediatric Central Review Board, National Cancer Institute (NCI), (2015-present)
Patient Expert, National Cancer Research Institute (NCRI), (2015-present)
Member, Society for Immunotherapy of Cancer (SITC), (2013-present)
Patient Representative, FDA, (2010-present)
Panel Member, Pediatric Oncologic Drugs Advisory Committee, (ODAC) FDA, (2010-present)
Member and Past Chair, Parent Advisory Council, New Approaches to Neuroblastoma Therapy (NANT), (2010-present)
Drug Appraisals, National Institute for Health and Care Excellence (NICE), (2015, 2016, 2018)
Pediatric Cancer Working Group Steering Committee, American Association for Cancer Research (AACR), (2015-2018)
Founding Member and Board Member, Coalition Against Childhood Cancer (CAC2), (2012-2019)
SKC has been invited to present at conferences and meetings around the world.
Organizer, Neuroblastoma Parent Global Symposium, Virtual (2020)
Advocate, Strategy Forum for BET Inhibitors, ACCELERATE, Virtual - Global (2020)
Advocate, Strategy Forum for Epigenetic Modifiers, ACCELERATE, Philadelphia (2020)
Advocate, Medulloblastoma in the Mountains, Whistler, Canada (2019)
Presenter, CNCF Conference, Relapse Road, Chicago IL (2019)
Participant, ACCELERATE Pediatric Oncology Conference, Brussels, Belgium (2019-2020)
Panel Member, Closed Preclinical Drug Development, AACR Pediatric Cancer Working Group, Atlanta, GA (2019)
Participant, International Multi-stakeholder Workshop, ITCC-P4, Amsterdam, Netherlands (2018)
Participant, Pediatric Cancer Round Table, Canadian Institute of Cancer Research (CIHR-ICR) Ottawa, Canada (2018)
Panel Member, Relapse Road, ANR/CNCF Parent Education Conference, San Francisco, CA (2018)
Panel Member, FDA/OCE Public Meeting on Relevant Molecular Targets in Pediatric Cancers, Silver Spring, MD (2018)
Panel Member, 2nd Pediatric Precision Oncology Conference, New England Journal of Medicine forum, Scottsdale, AZ (2018)
Presenter, FACTOR Osteosarcoma Conference, Collaborative Funding Model, Miami, FL (2018)
Presenter, International Society of Pediatric Oncology (SIOP), Oral and Poster Sessions, Washington, DC (2017)
Panel Member, AACR Annual Meeting, Pediatric Cancer Drug Development, New Orleans, LA (2016)
Organizing Committee and presenter, CAC2 Research Conference, Cold Spring Harbor, NY (2016)
Advocate Member, AACR Pediatric Cancer Predisposition Workshop, Boston, MA (2016)
Presenter, Parent Decisions: Breaking Bad News, Advances in Neuroblastoma Research (ANR), Cairns, Australia (2016)
Panel member, NCI Genomics Workshop, Advocate, Embryonal tumor pane, Bethesda, MD (2015)
Presenter, Bristol-Myers Squibb Advocate Council meeting, Philadelphia, PA (2015)
Presenter, The International Society for Pediatric Oncology (SIOP), Auckland, New Zealand (2011)
Presenter, Neuroblastoma Children’s Cancer Alliance/SKC EU, London, UK (2011-2019)
Presenter, Children’s Neuroblastoma Cancer Foundation (CNCF), (2010-2012)
Educational Presenter, Children’s Oncology Group (COG), Anaheim, CA (2010-2012)
Solving Kids' Cancer advocates for systemic improvements in the research enterprise and initiates novel clinical trials for children battling the deadliest childhood cancers. Experts agree that cures will come through multimodal combinations and approaches. SKC supports innovative therapies with strong rationale for improved outcomes for children who need it the most.
- SKC has funded 40 pediatric cancer research projects, 14 studies are currently enrolling or due to open.
28 of these projects represent clinical trials accruing hundreds of children at cancer centers in 5 countries.
SKC has supported 12 preclinical investigative projects that studied new targets, modalities, and delivery mechanisms.
SKC has initiated 4 transatlantic clinical trials, with two more in the planning, expanding access to children worldwide.
SKC has collaboratively funded 26 projects with 21 charity partners.
- SKC has supported ground-breaking clinical trials testing four different oncolytic viruses, dendritic cell and whole tumor vaccines, antibodies in combination with other agents and cellular therapies, targeted small molecules, emerging technologies such as high-intensity focused ultrasound, and convection-enhanced delivery, T cell CARs, and CTLs, next-generation precision medicine, and haploidentical stem cell transplant.
SKC has issued 7 requests for proposals with plans to issue 2 more to address unmet needs in solid tumors.